News & Press

  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    Non regulatory press release

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth...

  • Strengthened patent protection for arfolitixorin in Japan

    Non regulatory press release

    GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth...

  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

    Non regulatory press release

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

    Regulatory press release

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Isofol's CEO Ulf Jungnelius has subscribed for all warrants

    Non regulatory press release

    GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First...

  • A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

    Regulatory press release

    GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First...

  • AGENT study update with regards to COVID-19

    Non regulatory press release

    GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol’s rights issue oversubscribed

    Regulatory press release

    GOTHENBURG, Sweden, June 3, 2020 - Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market:...

  • Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

    Non regulatory press release

    GOTHENBURG, Sweden, May 29, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

    Regulatory press release

    GOTHENBURG, Sweden, May 14, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million

    Regulatory press release

    GOTHENBURG, Sweden, May 7, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • Information in relation to COVID-19

    Non regulatory press release

    GOTHENBURG, Sweden, April 2, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million

    Regulatory press release

    GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin

    Non regulatory press release

    GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • The first patient included in Japan in Isofol's Phase 3 AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...

  • Gene expression analysis method has been validated by a commercial laboratory

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...

  • Over 200 patients now randomized in the Global Phase 3 AGENT Study

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...

  • The Phase 1/2a study ISO-CC-005 is completed

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...

  • The first patient included in Australia in Isofol's Phase 3 AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...

  • Patent approved in Japan for Isofol’s drug candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)....

  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    Regulatory press release

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

    Non regulatory press release

    GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol's board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company

    Regulatory press release

    GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer

    Non regulatory press release

    GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

    Non regulatory press release

    GOTHENBURG, Sweden, September 29, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

    Non regulatory press release

    GOTHENBURG, Sweden, September 12, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer

    Non regulatory press release

    GOTHENBURG, Sweden, August 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

    Non regulatory press release

    GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Election of Three New Board Members

    Non regulatory press release

    GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today...

  • Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor

    Non regulatory press release

    GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Reports All Employees Participate in Newly Created Share Warrant Program

    Non regulatory press release

    GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol has participated in the Empowered Patient Podcast

    Non regulatory press release

    In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO...

  • Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    Regulatory press release

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...

  • Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    Non regulatory press release

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    Non regulatory press release

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    Regulatory press release

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...

  • New Chairman and extended board at Isofol Medical AB (publ)

    Regulatory press release

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling...

  • Patent approved in the United States for Isofol’s drug candidate arfolitixorin

    Regulatory press release

    The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical...

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    Non regulatory press release

    In connection to this year's major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/))...

  • Isofol announces that an abstract with new research resultshas been published for this year's ASCO congress in Chicago

    Regulatory press release

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year's annual...

  • Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process

    Regulatory press release

    In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States...

  • Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels...

  • Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007

    Regulatory press release

    The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult...

  • Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

    Non regulatory press release

    Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name...

  • Isofol reports successful outcome from the scientific advice with the EMA

    Regulatory press release

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines...